{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:42Z","timestamp":1791993942696,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011797","name":"Turku University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005423","name":"Uppsala University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire International GmbH"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ymgme.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T18:58:15Z","timestamp":1542049095000},"page":"169-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study"],"prefix":"10.1016","volume":"126","author":[{"given":"Frank","family":"Weidemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinrad","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kralewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Siwy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.11.005_bb0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","article-title":"Multicenter Female Fabry Study (MFFS) \u2013 clinical survey on current treatment of females with Fabry disease","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/08035320600618825","article-title":"The Mainz Severity score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease","volume":"95","author":"Beck","year":"2006","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0045","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfg349","article-title":"A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate","volume":"18","author":"Hoek","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0050","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/CIRCULATIONAHA.105.168237","article-title":"ACCF\/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance","volume":"112","author":"Budoff","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jmri.10262","article-title":"Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences","volume":"17","author":"Alfakih","year":"2003","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0060","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0070","first-page":"539","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association","volume":"18","author":"Cerqueira","year":"2002","journal-title":"Int. J. Cardiovasc. Imaging"},{"issue":"2003","key":"10.1016\/j.ymgme.2018.11.005_bb0075","first-page":"1091","volume":"16","author":"Cheitlin","year":"2003","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0085","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ndt\/14.6.1480","article-title":"Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease","volume":"14","author":"Hayano","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/01.CIR.44.1.130","article-title":"Approaches to sudden death from coronary heart disease","volume":"44","author":"Lown","year":"1971","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0095","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0100","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/prca.200800024","article-title":"CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics","volume":"2","author":"Coon","year":"2008","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/prca.201000155","article-title":"Human urinary peptide database for multiple disease biomarker discovery","volume":"5","author":"Siwy","year":"2011","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0110","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/elps.201200708","article-title":"Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications","volume":"34","author":"Stalmach","year":"2013","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020534","article-title":"A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy","volume":"6","author":"Kistler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0120","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/elps.200500827","article-title":"Biomarker discovery by CE-MS enables sequence analysis via MS\/MS with platform-independent separation","volume":"27","author":"Z\u00fcrbig","year":"2006","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Statist. Soc. B"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0135","unstructured":"National Kidney Foundation, A to Z Health Guide: Glomerular Filtration Rate https:\/\/www.kidney.org\/atoz\/content\/gfr (Accessed May 17, 2017)."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1532-429X-16-14","article-title":"Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis","volume":"16","author":"Schumm","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0160","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0170","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.109.912774","article-title":"Circulating biomarkers of collagen metabolism in cardiac diseases","volume":"121","author":"L\u00f3pez","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0175","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007124","article-title":"Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy","volume":"7","author":"Aguiar","year":"2018","journal-title":"J. Am. Heart Assoc"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J. Am. Heart Assoc"},{"key":"10.1016\/j.ymgme.2018.11.005_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl. 16","key":"10.1016\/j.ymgme.2018.11.005_bb0190","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/joneph\/23.S16.S199","article-title":"Fabry disease: perspectives of urinary proteomics","volume":"23","author":"Cuccurullo","year":"2010","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0195","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0200","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0886022X.2010.516859","article-title":"Study of urinary proteomes in Anderson-Fabry disease","volume":"32","author":"Vojtov\u00e1","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0205","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nm0511-553","article-title":"Scraping fibrosis: UMODulating renal fibrosis","volume":"17","author":"Eddy","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2018.11.005_bb0210","unstructured":"D. Hughes, A. Linhart, A. Gurevich, A. Joseph, M. Thakur, S. Feriozzi, Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in the Fabry Outcome Survey, Presented at: Society for the Study of Inborn Errors of Metabolism Annual Symposium, September 6\u20139, 2016, Rome, Italy, Poster no. 528."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218303603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218303603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:28:44Z","timestamp":1775266124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218303603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1096719218303603"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Shire International GmbH and The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}